Special Offer! - Free Pharmacy Design - Limited Time Offer, Hurry Up & Register Now

My Cart
In stock

TAXOTERE 20 MG/ML SOLUTION FOR INFUSION 1ml

In stock
Only 1 left
SKU
10331015080

TAXOTERE 20 MG/ML SOLUTION FOR INFUSION 1ml contains Docetaxel, an anti-cancer medication used to treat various solid tumors, including breast, lung, prostate, gastric, and head and neck cancers. It works by inhibiting cancer cell growth and is administered intravenously under medical supervision. Pre-medication is often required to manage potential side effects.

TAXOTERE 20 MG/ML SOLUTION FOR INFUSION 1ml: Advanced Cancer Treatment

TAXOTERE (Docetaxel) 20 MG/ML SOLUTION FOR INFUSION 1ml is a potent anti-cancer medication used in the treatment of various types of cancer. This solution is administered intravenously by healthcare professionals and works by interfering with the growth and spread of cancer cells in the body. It is a cornerstone therapy in oncology, often used alone or in combination with other anti-cancer agents.

As referenced on leading pharmaceutical and e-commerce platforms like Nahdionline, , and , products of this nature are integral to modern cancer protocols, designed to provide targeted action against malignant cells. Its precise formulation ensures effective delivery of the active ingredient, Docetaxel, to where it is needed most.

Benefits of Use:

TAXOTERE is clinically proven for its efficacy in treating a range of cancers, including:

  • Breast Cancer (adjuvant and metastatic)
  • Non-Small Cell Lung Cancer
  • Prostate Cancer (hormone-refractory metastatic)
  • Gastric Adenocarcinoma
  • Head and Neck Cancer

It helps in slowing the progression of the disease, reducing tumor size, and improving patient outcomes in appropriate cases. Its versatility makes it a valuable option in various treatment regimens.

How to Use:

TAXOTERE 20 MG/ML SOLUTION FOR INFUSION 1ml must be administered under the supervision of a qualified healthcare professional experienced in the use of anti-neoplastic agents. The following are general guidelines:

  1. Preparation: The solution is diluted in an appropriate infusion solution (e.g., 0.9% sodium chloride or 5% glucose) before administration.
  2. Administration: It is administered as a 1-hour intravenous infusion.
  3. Dosage: The dose and frequency of administration are highly individualized based on the patient's specific cancer type, stage, body surface area, and overall health condition.
  4. Pre-medication: Patients typically receive pre-medication with corticosteroids (such as dexamethasone) to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
  5. Monitoring: Regular blood tests and clinical assessments are crucial during treatment to monitor for side effects and treatment efficacy.

Caution & Warnings:

  • Administration: This medication must only be administered by medical personnel trained in chemotherapy administration in a facility equipped to manage potential adverse reactions.
  • Hypersensitivity Reactions: Severe hypersensitivity reactions can occur, requiring immediate medical intervention. Pre-medication is essential.
  • Bone Marrow Suppression: TAXOTERE can cause significant bone marrow suppression, leading to neutropenia (low white blood cell count), anemia, and thrombocytopenia (low platelet count). Close monitoring of blood counts is mandatory.
  • Fluid Retention: Patients may experience fluid retention, which can manifest as peripheral edema, pleural effusion, or ascites. Corticosteroid pre-medication helps mitigate this.
  • Neurotoxicity: Peripheral neuropathy (numbness, tingling, weakness) is a common side effect and should be monitored.
  • Hepatic Impairment: Dosage adjustments may be necessary for patients with liver function impairment. Liver function tests should be performed regularly.
  • Pregnancy and Lactation: TAXOTERE can cause fetal harm and is contraindicated during pregnancy. Women of childbearing potential should use effective contraception. It is not known if Docetaxel is excreted in human milk, so breastfeeding should be discontinued during treatment.
  • Drug Interactions: Caution is advised when co-administering TAXOTERE with drugs that are potent inhibitors or inducers of CYP3A4, as this can alter Docetaxel metabolism.

Ingredients:

  • Active Ingredient: Docetaxel 20 mg/ml
  • Excipients: Polysorbate 80, Ethanol (approximately 50% v/v)

Product Details:

  • Product Name: TAXOTERE 20 MG/ML SOLUTION FOR INFUSION
  • Strength: 20 mg/ml
  • Volume: 1ml per vial
  • Form: Solution for Infusion
  • Manufacturer: Sanofi-Aventis
  • Package Type: Single-use vial
  • Storage: Store between 2°C and 25°C, protected from light. Do not freeze.
More Information
Gtin 1-5079-20
Recommended Sale Price 461.7
Is Wasfaty Product No
Brand Not Defined
Ingredient Name DOCETAXEL
SFDA Reg. No 1-5079-20
IBC 1-5079-20
Drug Type Prescription
Scientific Name Docetaxel
Strength 20 mg/ml
Strength Unit mg/ml
Form Solution for infusion
Admin Route Intravenous
Size 1 ml
Size Unit ml
Package Types Vial
Package Size 1ml
shelfLife 24 months
Storage conditions Store vials between 2°C and 25°C. Do not freeze. Protect from light.
Refrigerator Storage No
Distribute area Saudi Arabia